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Abstract:  We  have  in  vitro  tested  the  ability  of  common,  commercially  available, 
cholinesterase reactivators (pralidoxime, obidoxime, methoxime, trimedoxime and HI-6) to 
reactivate  human  acetylcholinesterase  (AChE),  inhibited  by  five  structurally  different 
organophosphate pesticides and inhibitors (paraoxon, dichlorvos, DFP, leptophos-oxon and 
methamidophos). We also tested reactivation of human butyrylcholinesterase (BChE) with 
the aim of finding a potent oxime, suitable to serve as a ―pseudocatalytic‖ bioscavenger in 
combination with this enzyme. Such a combination could allow an increase of prophylactic 
and therapeutic efficacy of the administered enzyme. According to our results, the best  
broad-spectrum  AChE  reactivators  were  trimedoxime  and  obidoxime  in  the  case  of 
paraoxon,  leptophos-oxon,  and  methamidophos-inhibited  AChE.  Methamidophos  and 
leptophos-oxon were quite easily reactivatable by all tested reactivators. In the case of 
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methamidophos-inhibited  AChE,  the  lower  oxime  concentration  (10
−5  M)  had  higher 
reactivation ability than the 10
−4 M concentration. Therefore, we evaluated the reactivation 
ability  of  obidoxime  in  a  concentration  range  of  10
−3–10
−7  M.  The  reactivation  of 
methamidophos-inhibited AChE with different obidoxime concentrations resulted in a bell 
shaped curve with maximum reactivation at 10
−5 M. In the case of BChE, no reactivator 
exceeded 15% reactivation ability and therefore none of the oximes can be recommended 
as a candidate for ―pseudocatalytic‖ bioscavengers with BChE. 
Keywords:  acetylcholinesterase;  butyrylcholinesterase;  in  vitro;  nerve  agent; 
organophosphate; pesticide; reactivator; oxime; scavenger 
 
1. Introduction 
Organophosphates  (OPs)  are  widely  used  as  pesticides  (e.g.,  parathion,  methamidophos)  in 
agriculture, as plasticizers and flame retardants (cresyl diphenyl phosphate, triaryl phosphate) in the 
industry, and as toxic chemical warfare agents (nerve agents, e.g., sarin, VX). OP pesticide poisonings 
causes tens of thousands of deaths every year in the whole world [1]. OP pesticides irreversibly inhibit 
enzymes acetylcholinesterase (AChE; EC 3.1.1.7) and butyrylcholinesterase (BChE; EC 3.1.1.8) by 
phosphorylation or phosphonylation (phosphylation) of the serine hydroxyl group at the enzyme’s 
active site. Inhibited AChE cannot cleave the neuromediator acetylcholine which is then accumulated 
in the nerve synapses and causes cholinergic crisis, which can lead to death [2]. Resulting enzyme 
complexes underlie secondary reactions, which may affect the efficacy of medical treatment and the 
diagnosis  [3].  Phosphylated  AChE  and  BChE  may  undergo  spontaneous  dealkylation,  through  
alkyl–oxygen bond scission or P–N bond scission in case of tabun [3–5]. This unimolecular process is 
called aging and it results in an irreversibly inactivated enzyme [3]. Negatively charged adduct is then 
stabilized by interaction with the catalytic His 440 [6]. Reactivation is limited by aging of the AChE 
and high concentrations of pesticides. Aging of AChE takes longer with diethyl-OPs compounds than 
with dimethyl-OPs; half-lives of dimethyl-OPs are 3.7 h, and of diethyl-OPs, 31 h. For this reason, the 
oxime therapy should begin as soon as possible following intoxication. Oximes may be effective if 
started within about 120 hours for diethyl-OP poisoning and 12 hours for dimethyl-OP poisoning 
(therapeutic window, four times the half-life) [7–10]. Additional secondary reaction is a spontaneous 
reactivation,  leading  to  recovery  of  AChE  or  BChE  function  [3].  Spontaneous  reactivation  is  the 
combination of two parallel processes: dephosphylation and aging [6]. Kinetics of aging, reactivation 
and spontaneous dephosphylation depends on the source of cholinesterase and chemical structure of 
OP and reactivator. 
Current therapy of OP poisonings involves the administration of anticholinergic drug (atropine), 
anticonvulsants (diazepam) and for the recovery of function of inhibited AChE antidotes from the 
group  of  pyridinium or bispyridinium  aldoximes (oximes) are used. Therapeutic efficacy of these 
compounds depends on their chemical structure and also type of OP inhibitor. Prophylaxis is realized 
by administration of reversible inhibitors of AChE (e.g., carbamate pyridostigmine) [11]. Relatively 
new approach in treatment of OP poisonings is using of enzyme bioscavengers. These bioscavengers Int. J. Mol. Sci. 2011, 12                       
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are able to catch and neutralize toxic OP molecules in the bloodstream, before they can reach their 
physiological target—AChE in different tissues [12]. They can prevent post-exposure incapacitation 
and toxic effects that are commonly observed in animals treated by traditional antidotal regimen [13]. 
Many scientific efforts have been focused on butyrylcholinesterase (BChE) as a bioscavenger capable 
of  sequestering  molecules  of  nerve  agents  or  pesticides  from  the  bloodstream  and  serving  as  
OP-nonspecific  prophylactics  [12,14].  BChE  was  recently  evaluated  in  several  clinical  studies  
(phase I) in USA. 
The aim of our work was to test and summarize reactivation ability of common, commercially 
available  AChE  reactivators  (methoxime,  pralidoxime,  obidoxime,  trimedoxime  and  HI-6,  see  
Figure 1) and to evaluate their potential usefulness in the treatment of OP pesticide poisoning. 
Figure 1. Structures of tested oxime reactivators. 
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We  have  tested  their  ability  to  reactivate  human  AChE  inhibited  by  five  structurally  different 
pesticides in vitro. Moreover, we tested reactivation of BChE, in parallel, with the aim of finding a 
potent  oxime,  suitable  of  serving  in  combination  with  this  enzyme  (administered  as  prophylactic 
antidote or occurring naturally in blood) as a ―pseudocatalytic‖ bioscavenger. Such a combination 
could allow an increase of prophylactic and therapeutic efficacy of the administered enzyme and also a 
decrease in the amount of enzyme necessary and cost of such a bioscavenger [15,16]. 
2. Results and Discussion 
Measured  values  of  reactivation  ability  of  tested  oxime  reactivators  are  summarized  in  
Tables 1 and Table 2. Int. J. Mol. Sci. 2011, 12                       
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Table 1. Reactivation ability of five oximes to reactivate OP-inhibited human erythrocyte 
AChE,  at  concentrations  10
−4  M  and  10
−5  M  (%,  mean  value  of  three  independent 
determinations; time of reactivation 10 min; pH 7.4; temperature 25 ° C). 
 
AChE 
Paraoxon [17]  Dichlorvos  DFP [18]  Leptophos-oxon [19]  Methamidophos 
100 μM  10 μM  100 μM  10 μM  100 μM  10 μM  100 μM  10 μM  100 μM  10 μM 
Mean  SD  Mean  SD  Mean  SD  Mean  SD  Mean  SD  Mean  SD  Mean  SD  Mean  SD  Mean  SD  Mean  SD 
Methoxime  23.4  4.5  4.3  1.5  0  0  0.2  0.6  6.4  0.5  1.5  0.5  52.6  0.5  11.9  0.9  61.7  2.4  68.1  11.4 
Pralidoxime  18.1  0.9  1.3  0.9  2.6  0.6  0.2  0.6  2.3  0.2  0  0  13.2  0.9  4.1  1.3  53.4  3.1  53.8  22.6 
Obidoxime  96.8  0.9  59.4  0.9  0  0  0.6  0.1  17.1  0.1  7.4  0.5  50.3  0.9  31.4  0.2  5.8  4.8  57.0  18.7 
Trimedoxime  86.0  1.6  45.3  0.8  0  0  0  0  23.8  0.2  6.4  0.2  51.3  0.5  26.4  2.7  9.4  7.5  53.1  10.9 
HI-6  16.1  0.2  3.9  0.9  0  0  0.6  1.1  0  0  0  0  32.8  8.0  11.6  0.4  37.4  12.3  75.2  14.6 
Table  2.  Reactivation  ability  of  five  oximes  to  reactivate  OP-inhibited  human  plasma 
BChE,  at  concentrations  10
−4  M  and  10
−5  M  (%,  mean  value  of  three  independent 
determinations; time of reactivation 10 min; pH 7.4; temperature 25 ° C).  
 
BChE 
Paraoxon [17]  Dichlorvos  DFP [18]  Leptophos-oxon [19]  Methamidophos 
100 μM  10 μM  100 μM  10 μM  100 μM  10 μM  100 μM  10 μM  100 μM  10 μM 
Mean  SD  Mean  SD  Mean  SD  Mean  SD  Mean  SD  Mean  SD  Mean  SD  Mean  SD  Mean  SD  Mean  SD 
Methoxime  6.1  0.6  0.9  0.8  0.2  0.1  0.2  0.1  8.2  1.3  0.8  0.5  6.4  0.4  1.9  1.8  4.8  0.2  1.0  0.2 
Pralidoxime  5.5  0.1  1.0  0.3  1.0  0.1  0.4  0.2  6.4  0.8  0.7  0.1  2.3  1.8  0  0  3.5  0.3  0  0 
Obidoxime  9.9  0.4  2.2  0.4  3.1  0.2  1.6  0.4  9.5  1.0  1.5  0.6  14.3  0.6  6.5  4.2  4.2  0.3  1.0  0.2 
Trimedoxime  12.1  1.7  1.3  0.3  1.2  0.1  0.4  0.2  7.3  0.5  0.8  0.5  8.5  2.4  2.1  0.4  5.2  0.7  0.6  0.8 
HI-6  2.3  0.3  0.8  0.5  0.6  0.1  0.4  0.1  3.8  0.1  0.7  0.2  5.6  4.9  0  0  4.8  0.2  0.1  0.2 
Reactivators  were  evaluated  in  vitro,  in  concentrations  10
−4  M  and  10
−5  M,  which  are  usually 
attainable in plasma within clinical treatment in the hospital in the case of intoxication by OPs [20]. 
Our  results  demonstrated  that  the  best  broad-spectrum  AChE  reactivators  after  10  minutes  of 
reactivation, are trimedoxime and obidoxime, because they reached more than 50% of reactivation in 
the  case  of  paraoxon,  leptophos-oxon  and  methamidophos-inhibited  AChE.  DFP-  and  
dichlorvos-inhibited AChE were not sufficiently reactivated. Methamidophos and leptophos-oxon are 
quite easily reactivatable by all tested reactivators. In reactivation of dichlorvos-, paraoxon-, DFP- and 
leptophos-oxon-inhibited  AChE,  a  higher  oxime  concentration  caused  higher  reactivation  of  the 
phosphorylated enzyme. Reverse behavior was observed for methamidophos-inhibited enzyme, where 
the  maximum  reactivation  ability  was  achieved  with  lower  oxime  concentration.  Therefore,  we 
investigated the relationship between oxime concentration and type of inhibitor used. Obidoxime was 
selected as a suitable model oxime and its reactivation ability was estimated in a concentration range 
(depending  on  the  inhibitor)  of  10
−8–10
−2  M  (Figures  2–6).  As  a  result,  we  obtained  bell-shaped 
dependencies of reactivation ability on obidoxime concentration for each inhibitor.  Int. J. Mol. Sci. 2011, 12                       
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Figure 2. Relationship between obidoxime concentration and corresponding reactivation 
ability of methamidophos-inhibited AChE. 
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Figure 3. Relationship between obidoxime concentration and corresponding reactivation 
ability of paraoxon-inhibited AChE. 
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Figure 4. Relationship between obidoxime concentration and corresponding reactivation 
ability of dichlorvos-inhibited AChE. 
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Figure 5. Relationship between obidoxime concentration and corresponding reactivation 
ability of DFP-inhibited AChE. 
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Figure 6. Relationship between obidoxime concentration and corresponding reactivation 
ability of leptophos-oxon-inhibited AChE. 
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Maximum  level  of  reactivation  for  each  inhibitor  was  achieved  at  different  obidoxime 
concentrations  and,  especially  for  methamidophos;  the  maximum  was  shifted  towards  lower 
concentrations. While the lower oxime concentration (left side of the graph), causes practically only 
reactivation  of  the  phosphorylated  enzyme,  on  increasing  concentration  enzyme  inhibition  with 
reactivator occurs (right side of the graph) [21]. This is the reason, why the course of the reactivation 
curve  is  always  bell-shaped  in  the  whole  concentration  range  of  oxime  [22,23].  Therefore,  the 
reactivation  process  itself  is  characterized  in the increasing  and  the decreasing parts  of  the  curve 
showing  both  reactivation  and  inhibition  of  liberated  intact  AChE  by  the  reactivator  itself.  Each 
reactivator varies in the optimal concentration for reactivation. Lower concentrations were optimal for 
some oximes (e.g., 10
−5 M) [22,24,25]. Another important factor affecting the reactivation process and 
the course of the reactivation curve is the formation of phosphorylated oximes during reactivation [26] 
as their presence causes re-inhibition of the enzyme. The probability of their formation increases with 
higher enzyme or oxime concentrations [27]. There is evidence that phosphorylated oximes could 
decompose in blood because human plasma paraoxonase may be capable of degrading dimethoxy- and 
diethoxy-phosphorylated oximes derived from obidoxime and trimedoxime [28]. Int. J. Mol. Sci. 2011, 12                       
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Aging  of  inhibited  enzyme  could  also  decrease  reactivation  potency.  In  this  study,  measured 
reactivation ability was not corrected for this phenomenon. 
According  to  our  results,  reactivation  ability  of  tested  oximes  for  BChE  was  very  low  in 
comparison with values measured for AChE. Comparable results, with reactivation of OP-inhibited 
BChE, were also obtained by Aurbek et al. [29]. 
3. Experimental Section 
Cholinesterase reactivators used in this study were synthesized in our lab or purchased from Leciva 
(Czech Republic), Merck (Germany) and Phoenix Chemicals Ltd. (United Kingdom). Purity of all the 
AChE  reactivators  utilized  was  tested  using  TLC  (DC-Alufolien  Cellulose  F;  mobile  phase  
n-butanol-acetic acid-water = 5:1:2; detection by Dragendorff reagent) and NMR (Varian Gemini 300, 
Palo Alto, CA, USA), and their purity was higher than 98%. Pesticides and inhibitors with a minimum 
purity of 90% were purchased from Dr. Ehrenstorfer (Augsburg, Germany) and Sigma-Aldrich (Czech 
Republic). All other chemicals used in this study were of analytical purity and were purchased from 
Sigma-Aldrich  (Czech  Republic).  Reactivation  potency  of  five  oximes  (methoxime,  pralidoxime, 
obidoxime, trimedoxime and HI-6) was tested by in vitro screening test. For this purpose modified 
Ellman’s method was used [17–19,25,30–32]. Paraoxon (diethyl 4-nitrophenyl phosphate, the active 
―toxic‖  form  of  pesticide  parathion),  dichlorvos  (2,2-dichlorovinyl  dimethyl  phosphate),  DFP 
(diisopropyl  fluorophosphate),  leptophos-oxon  (O-[4-bromo-2,5-dichlorophenyl]  O-methyl 
phenylphosphonate)  and  methamidophos  (O,S-dimethyl  phosphoramidothioate)  were  selected  as 
suitable model OP inhibitors. Human erythrocyte hemolyzate was used as a source of AChE and 
human plasma as a source of BChE. The blood samples were collected from healthy volunteers from 
the  vein  into  a  disposable  syringe  containing  3.8%  sodium  citrate  (the  ratio  blood/citrate  was  
1:10 w/w). The citrated blood was centrifuged for 20 min at 2856 ×  g, the plasma was removed as 
supernatant, frozen and was kept under −80 °C  (source of BChE). The erythrocytes were washed three 
times with phosphate buffer (PB; 0.1 M, pH 7.4) and then hemolyzed in PB (0.01 M, pH 7.4) in a ratio 
1:10 (w/w), frozen and kept under −80 °C  (source of AChE). Enzymes were inhibited to 5 % of their 
original  activity  using  concentration  corresponding  to  IC95  (concentration  which  causes  95% 
inhibition). Time of enzyme inhibition (equivalent to 7 ×  T1/2) was calculated separately for each 
compound from experimentally determined half-life (T1/2) of reaction between enzyme and inhibitor. 
Detailed data about used concentrations of inhibitors and time of inhibition are summarized in Table 3. 
The inhibition of AChE was started in plastic cuvettes by addition of inhibitor solution in isopropanol 
to the mixture of phosphate buffer (0.05 M, pH 7.4) and hemolyzate (activity before inhibition was set 
to 10 U/L) or plasma (activity was set to 13.3 U/L). Concentration of isopropanol in the sample was 
5%. This concentration had no significant influence on the activity of both cholinesterases. Blind 
samples with uninhibited enzyme were incubated for given time (Table 3) with isopropanol in final 
concentration  5%  [25,32].  Inhibited  enzymes  were  then  immediately  incubated  for  10  min  with 
solution of reactivator in phosphate buffer (0.05 M, pH 7.4) at concentrations 10
−4 M and 10
−5 M (and 
10
−8–10
−2 M for obidoxime). Mixture was diluted 20 times before the measurement. Activity of AChE 
(BChE) was determined spectrophotometrically by modified method according to Ellman [30]. The Int. J. Mol. Sci. 2011, 12                       
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final concentration of DTNB and acetylthiocholine or butyrylthiocholine in the mixture was 10
−3 M. 
All results were corrected for oximolysis. Reactivation potency was calculated from the formula: 
% R = [1 − (a0 − ar)/(a0 − ai)] ×  100 
where % R is percent of reactivation, a0 is activity of intact enzyme, ai is activity of inhibited enzyme 
and ar is activity of reactivated enzyme minus oximolysis. Data were not corrected for aging because 
enzyme was reactivated at the latest one hour after inhibition and time of incubation with oxime was 
relatively  short  (10  min.)  Detailed  description  of  the  method  can  be  found  in  publications  of  
Musilova et al. [31,32]. 
Table 3. Concentration of inhibitors (IC95) and time of inhibition (7 ×  T1/2) for AChE and 
BChE used in experiment. 
  AChE  BChE 
Inhibitor   IC95 (M)  7 ×  T1/2 (min)  IC95 (M)  7 ×  T1/2 (min) 
Paraoxon  3.38 ×  10
−6  2.17  1.41 ×  10
−7   1.82 
Dichlorvos  3.30 ×  10
−4  0.32  2.08 ×  10
−6   2.20 
DFP  5.00 ×  10
−6   0.93  8.30 ×  10
−8   1.75 
Leptophos−oxon  4.16 ×  10
−7   2.45  7.06 ×  10
−6   0.75 
Methamidophos  4.26 ×  10
−5   2.22  2.08 ×  10
−4   2.83 
4. Conclusions 
According  to  our  results,  bisquaternary  oximes  seem  to  be  more  potent  reactivators  of  
pesticide-inhibited AChE than monoquaternary pralidoxime. No reactivator achieved sufficient ability 
to reactivate OP pesticide-inhibited BChE, and therefore none of the oximes can be recommended as a 
candidate for ―pseudocatalytic‖ bioscavengers with BChE. Because of this, a larger group (not only the 
currently available ones) of reactivators need to be tested to better understand the structure–activity  
relationship which would then help in the synthesis of new reactivators of BChE—―rational synthesis 
of BChE reactivators‖. 
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